(Q43277549)

English

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

scientific article published on 11 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

object named as

Henry Krum

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

author name string

Michael A Weber

1

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Henry Black

2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

George Bakris

3

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Stuart Linas

5

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Robert Weiss

6

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Jennifer V Linseman

7

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Brian L Wiens

8

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Marshelle S Warren

9

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Lars H Lindholm

10

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

language of work or name

0 references

publication date

11 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

9699

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1423-1431

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased plasma endothelin level in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased plasma levels of endothelin in diabetic patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated plasma endothelin-1 levels in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The fallback procedure for evaluating a single family of hypotheses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Systolic pressure is all that matters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of low-dose spironolactone in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of spironolactone in the treatment of patients with refractory hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961500-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)61500-2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43277549&oldid=1985510453"